Cargando…
Relative Vaccine Effectiveness of the Third Dose of CoronaVac or BNT162b2 Following a Two-Dose CoronaVac Regimen: A Prospective Observational Cohort Study from an Adult Vaccine Center in Turkey
Coronavirus disease 2019 (COVID-19) continues to pose a threat to public health with the potential for the emergence of new variants. Vaccines are the milestones to control and slow down the damage of the pandemic. As of January 2021, a two-dose regimen with CoronaVac was authorized in Turkey. Due t...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9322864/ https://www.ncbi.nlm.nih.gov/pubmed/35891304 http://dx.doi.org/10.3390/vaccines10071140 |
_version_ | 1784756409168035840 |
---|---|
author | Sonmezer, Meliha Cagla Dizman, Gulcin Telli Erul, Enes Sahin, Taha Koray Saricaoglu, Tuğba Alp, Alparslan Tanriover, Mine Durusu Uzun, Omrum Unal, Serhat Akova, Murat |
author_facet | Sonmezer, Meliha Cagla Dizman, Gulcin Telli Erul, Enes Sahin, Taha Koray Saricaoglu, Tuğba Alp, Alparslan Tanriover, Mine Durusu Uzun, Omrum Unal, Serhat Akova, Murat |
author_sort | Sonmezer, Meliha Cagla |
collection | PubMed |
description | Coronavirus disease 2019 (COVID-19) continues to pose a threat to public health with the potential for the emergence of new variants. Vaccines are the milestones to control and slow down the damage of the pandemic. As of January 2021, a two-dose regimen with CoronaVac was authorized in Turkey. Due to the waning seroprevalence rate of SARS-CoV-2 over time, BNT162b2 or CoronaVac has been administered as the third dose following a two-dose CoronaVac regimen as a national vaccination policy. As of 14 January 2021, 5243 volunteers who received two doses of the CoronaVac vaccine at Hacettepe University Adult Vaccine Center were followed prospectively. In our study, relative vaccine effectiveness (VE(ff)) for the third dose of the CoronaVac was 58.24% and 87.27% for BNT162b2 in preventing symptomatic COVID-19 cases. There were no hospitalizations, intensive care unit admissions, or deaths in third-dose booster groups with either BNT162b2 or CoronaVac, yielding 100% effectiveness. Both homologous or heterologous third-dose boosters provided further protection against severe COVID-19 and should be prioritized as an effective strategy to combat the COVID-19 pandemic. |
format | Online Article Text |
id | pubmed-9322864 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-93228642022-07-27 Relative Vaccine Effectiveness of the Third Dose of CoronaVac or BNT162b2 Following a Two-Dose CoronaVac Regimen: A Prospective Observational Cohort Study from an Adult Vaccine Center in Turkey Sonmezer, Meliha Cagla Dizman, Gulcin Telli Erul, Enes Sahin, Taha Koray Saricaoglu, Tuğba Alp, Alparslan Tanriover, Mine Durusu Uzun, Omrum Unal, Serhat Akova, Murat Vaccines (Basel) Article Coronavirus disease 2019 (COVID-19) continues to pose a threat to public health with the potential for the emergence of new variants. Vaccines are the milestones to control and slow down the damage of the pandemic. As of January 2021, a two-dose regimen with CoronaVac was authorized in Turkey. Due to the waning seroprevalence rate of SARS-CoV-2 over time, BNT162b2 or CoronaVac has been administered as the third dose following a two-dose CoronaVac regimen as a national vaccination policy. As of 14 January 2021, 5243 volunteers who received two doses of the CoronaVac vaccine at Hacettepe University Adult Vaccine Center were followed prospectively. In our study, relative vaccine effectiveness (VE(ff)) for the third dose of the CoronaVac was 58.24% and 87.27% for BNT162b2 in preventing symptomatic COVID-19 cases. There were no hospitalizations, intensive care unit admissions, or deaths in third-dose booster groups with either BNT162b2 or CoronaVac, yielding 100% effectiveness. Both homologous or heterologous third-dose boosters provided further protection against severe COVID-19 and should be prioritized as an effective strategy to combat the COVID-19 pandemic. MDPI 2022-07-18 /pmc/articles/PMC9322864/ /pubmed/35891304 http://dx.doi.org/10.3390/vaccines10071140 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Sonmezer, Meliha Cagla Dizman, Gulcin Telli Erul, Enes Sahin, Taha Koray Saricaoglu, Tuğba Alp, Alparslan Tanriover, Mine Durusu Uzun, Omrum Unal, Serhat Akova, Murat Relative Vaccine Effectiveness of the Third Dose of CoronaVac or BNT162b2 Following a Two-Dose CoronaVac Regimen: A Prospective Observational Cohort Study from an Adult Vaccine Center in Turkey |
title | Relative Vaccine Effectiveness of the Third Dose of CoronaVac or BNT162b2 Following a Two-Dose CoronaVac Regimen: A Prospective Observational Cohort Study from an Adult Vaccine Center in Turkey |
title_full | Relative Vaccine Effectiveness of the Third Dose of CoronaVac or BNT162b2 Following a Two-Dose CoronaVac Regimen: A Prospective Observational Cohort Study from an Adult Vaccine Center in Turkey |
title_fullStr | Relative Vaccine Effectiveness of the Third Dose of CoronaVac or BNT162b2 Following a Two-Dose CoronaVac Regimen: A Prospective Observational Cohort Study from an Adult Vaccine Center in Turkey |
title_full_unstemmed | Relative Vaccine Effectiveness of the Third Dose of CoronaVac or BNT162b2 Following a Two-Dose CoronaVac Regimen: A Prospective Observational Cohort Study from an Adult Vaccine Center in Turkey |
title_short | Relative Vaccine Effectiveness of the Third Dose of CoronaVac or BNT162b2 Following a Two-Dose CoronaVac Regimen: A Prospective Observational Cohort Study from an Adult Vaccine Center in Turkey |
title_sort | relative vaccine effectiveness of the third dose of coronavac or bnt162b2 following a two-dose coronavac regimen: a prospective observational cohort study from an adult vaccine center in turkey |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9322864/ https://www.ncbi.nlm.nih.gov/pubmed/35891304 http://dx.doi.org/10.3390/vaccines10071140 |
work_keys_str_mv | AT sonmezermelihacagla relativevaccineeffectivenessofthethirddoseofcoronavacorbnt162b2followingatwodosecoronavacregimenaprospectiveobservationalcohortstudyfromanadultvaccinecenterinturkey AT dizmangulcintelli relativevaccineeffectivenessofthethirddoseofcoronavacorbnt162b2followingatwodosecoronavacregimenaprospectiveobservationalcohortstudyfromanadultvaccinecenterinturkey AT erulenes relativevaccineeffectivenessofthethirddoseofcoronavacorbnt162b2followingatwodosecoronavacregimenaprospectiveobservationalcohortstudyfromanadultvaccinecenterinturkey AT sahintahakoray relativevaccineeffectivenessofthethirddoseofcoronavacorbnt162b2followingatwodosecoronavacregimenaprospectiveobservationalcohortstudyfromanadultvaccinecenterinturkey AT saricaoglutugba relativevaccineeffectivenessofthethirddoseofcoronavacorbnt162b2followingatwodosecoronavacregimenaprospectiveobservationalcohortstudyfromanadultvaccinecenterinturkey AT alpalparslan relativevaccineeffectivenessofthethirddoseofcoronavacorbnt162b2followingatwodosecoronavacregimenaprospectiveobservationalcohortstudyfromanadultvaccinecenterinturkey AT tanrioverminedurusu relativevaccineeffectivenessofthethirddoseofcoronavacorbnt162b2followingatwodosecoronavacregimenaprospectiveobservationalcohortstudyfromanadultvaccinecenterinturkey AT uzunomrum relativevaccineeffectivenessofthethirddoseofcoronavacorbnt162b2followingatwodosecoronavacregimenaprospectiveobservationalcohortstudyfromanadultvaccinecenterinturkey AT unalserhat relativevaccineeffectivenessofthethirddoseofcoronavacorbnt162b2followingatwodosecoronavacregimenaprospectiveobservationalcohortstudyfromanadultvaccinecenterinturkey AT akovamurat relativevaccineeffectivenessofthethirddoseofcoronavacorbnt162b2followingatwodosecoronavacregimenaprospectiveobservationalcohortstudyfromanadultvaccinecenterinturkey |